Pidomod (CAS 121808-62-6), also known as primo, spectrum leyi, is an immunomodulator, suitable for patients with low immune function of the body, and can be used to prevent acute infection, shorten the course of disease, reduce the severity of the disease, can be used as an auxiliary drug during the acute infection period.Mainly used in children recurrent respiratory tract infection, urinary tract infection (urinary tract infection), chronic bronchitis also has therapeutic effect, to the virus.Influenza and viral herpes are effective.It can also be used for infection caused by pneumococcal pneumonia and escherichia coli, pseudomonas aeruginosa and proteus.Report OverviewDue to the COVID-19 pandemic and Russia-Ukraine War Influence, the global market for Product Name estimated at USD million in the year 2022, is projected to reach a revised size of USD million by 2028, growing at a CAGR of percent during the forecast period 2022-2028.The USA market for Pidotimod is estimated to increase from USD million in 2022 to reach USD million by 2028, at a CAGR of percent during the forecast period of 2023 through 2028.The China market for Pidotimod is estimated to increase from USD million in 2022 to reach USD million by 2028, at a CAGR of percent during the forecast period of 2023 through 2028.The Europe market for Pidotimod is estimated to increase from USD million in 2022 to reach USD million by 2028, at a CAGR of percent during the forecast period of 2023 through 2028.The global key manufacturers of Pidotimod include Active Peptide Company, Reco Tech, Manus Aktteva Biopharma, Joyochem, Changzhou Yinsheng Pharmaceutical and Dr. Reddy’s, etc. In 2021, the global top five players had a share approximately percent in terms of revenue.